A disease-modifying therapy to treat Parkinson’s disease has moved through a phase I clinical trial and is set to enter a phase II study, co-sponsor the Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced Thursday.

Richard L. Wahl, MD, will be taking over as head of radiology at Washington University School of Medicine and director of the Mallinckrodt Institute of Radiology this fall, the university announced Friday.

Progenics Pharmaceuticals, a producer of oncologic drugs, most notably a prostate-specific membrane antigen targeted therapy currently in clinical trials, has announced that the company will be hosting a conference call to review second quarter 2014 financials and other topics on Friday, Aug. 8.

A new method of molecular imaging captures the dysfunction of an oncoprotein—Akt/PKB, the activation of which is tied to dismal prognoses in cancer patients. High throughput time-resolved-FRET (fluorescence resonance energy transfer) was implemented to seek out Akt/PKB activation in breast cancer patients, which could have a significant impact on not only future research, but potentially individual patient management, according to a study published in the July issue of Cancer Research.

The quantitative imaging of myocardial blood flow has been gaining momentum in recent years, as is the use of F-18 flurpiridaz, which has been shown to reveal a clear demarcation of disease in patients with CAD, according to a first-in-human quantitative imaging study published July 28 in the Journal of Nuclear Medicine.

SAN ANTONIO, July 30, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the issuance of a United States patent entitled "Methods and compositions for the detection of cancer". The patent US 8,772,226 B2 was issued July 8, 2014.

IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has received combined clearances from the U.S. Food and Drug Administration (FDA) that will enable IBA to market-launch the Proton Therapy specific Cone Beam Computed Tomography (CBCT) solution.

The University of California San Francisco is creating a magical new world of woodland forests and cable cars in a family friendly molecular imaging and radiology suite, reports SF Gate.